Literature DB >> 9220399

A synthetic vaccinia virus promoter with enhanced early and late activity.

J M Hammond1, P G Oke, B E Coupar.   

Abstract

A synthetic vaccinia virus promoter (Psel) was constructed based upon sequences which increase activity of the P7.5 early/late promoter. Comparison of luciferase activity in lysates from cells infected with recombinant vaccinia viruses expressing the luciferase gene either under the control of the P7.5 promoter or Psel, demonstrated significantly enhanced activity mediated by Psel at both early and late times post infection. This promoter may be of considerable benefit in the construction of recombinant poxviruses where early foreign gene expression is important for generating a protective immune response in vaccinated animals, or in reporter/target gene expression in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220399     DOI: 10.1016/s0166-0934(97)00045-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  11 in total

1.  Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.

Authors:  Kathryn Ottolino-Perry; Sergio A Acuna; Fernando A Angarita; Clara Sellers; Siham Zerhouni; Nan Tang; J Andrea McCart
Journal:  Mol Oncol       Date:  2015-05-06       Impact factor: 6.603

2.  Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Authors:  James F Papin; Paulo H Verardi; Leslie A Jones; Francisco Monge-Navarro; Aaron C Brault; Michael R Holbrook; Melissa N Worthy; Alexander N Freiberg; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

3.  A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Authors:  Tae-Ho Hwang; Anne Moon; James Burke; Antoni Ribas; Joe Stephenson; Caroline J Breitbach; Manijeh Daneshmand; Naomi De Silva; Kelley Parato; Jean-Simon Diallo; Yeon-Sook Lee; Ta-Chiang Liu; John C Bell; David H Kirn
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

4.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019

5.  Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics.

Authors:  Patricia Grigg; Allison Titong; Leslie A Jones; Tilahun D Yilma; Paulo H Verardi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-29       Impact factor: 11.205

6.  Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination.

Authors:  A M Wolfe; K M Dunlap; A C Smith; M Y Bartee; E Bartee
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.

Authors:  Hajime Kurosaki; Motomu Nakatake; Teruhisa Sakamoto; Nozomi Kuwano; Masato Yamane; Kenta Ishii; Yoshiyuki Fujiwara; Takafumi Nakamura
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

Review 8.  Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.

Authors:  Shyambabu Chaurasiya; Yuman Fong; Susanne G Warner
Journal:  Cancers (Basel)       Date:  2020-06-26       Impact factor: 6.639

9.  Construction and characterization of a synthetic Baculovirus-inducible 39K promoter.

Authors:  Zhan-Qi Dong; Zhi-Gang Hu; Hai-Qing Li; Ya-Ming Jiang; Ming-Ya Cao; Peng Chen; Cheng Lu; Min-Hui Pan
Journal:  J Biol Eng       Date:  2018-12-04       Impact factor: 4.355

10.  Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression.

Authors:  Midori Yamashita; Mamoru Tasaki; Ryuji Murakami; Yukinori Arai; Takafumi Nakamura; Shinsuke Nakao
Journal:  Mol Ther Oncolytics       Date:  2021-02-04       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.